미국의 급성 뇌실외배액(EVD) 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 환자 유형별, 부문 예측(2025-2030년)

Market Size & Trends:

The U.S. acute external ventricular drain market size was valued at USD 86.5 million in 2024 and is projected to grow at a CAGR of 7.9% from 2025 to 2030. The growth is expected to be driven by the rising prevalence of non-traumatic hydrocephalus, increased demand for minimal or noninvasive neurosurgeries, and the rising adoption of technologically improved devices. With the growing incidence of accidents, sports injuries, and strokes, the demand for external ventricular drain (EVD) procedures is rising steadily.

As the aging population expands, the prevalence of conditions like strokes and aneurysms rises, further boosting the need for EVD procedures. For instance, according to the World Bank Group, the total population aged 65 and above in the U.S. was 49.98 million in 2018, increasing to 58.38 million in 2023. In addition, advancements in healthcare infrastructure and the rising number of emergency and trauma centers equipped to handle acute neurological cases contribute to market growth.

Technological innovations in EVD systems, such as improved catheter designs, antimicrobial coatings, and integrated monitoring capabilities, enhance patient outcomes and reduce infection risks, making these devices more appealing to healthcare providers. Hospitals and clinics increasingly adopt these advanced EVD systems to improve treatment efficiency and minimize complications. Moreover, the growing emphasis on minimally invasive neurosurgical techniques supports the demand for EVDs, as they offer a less invasive solution for managing CSF drainage than traditional surgical methods.

Another factor fueling market expansion is the rising healthcare expenditure in the U.S., coupled with favorable reimbursement policies for neurological procedures. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 7.5% in 2023, reaching USD 4.9 trillion, which amounts to USD 14,570 per person. Insurance coverage for EVD placements and related treatments ensures broader patient access, encouraging hospitals to invest in these devices. Furthermore, increased physician awareness about the benefits of early and effective CSF management in critical care settings drives higher adoption rates.

U.S. Acute External Ventricular Drain Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. acute external ventricular drain market report based on application, and patient type.

• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Traumatic Brain Injury
• Subarachnoid hemorrhage
• Intracerebral hemorrhage
• Other Non-Traumatic Hydrocephalus conditions
• Patient Type Outlook (Revenue, USD Million, 2018 - 2030)
• Pediatric
• Adult

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Patient Type
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Patient type outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Acute External Ventricular Drain Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Acute External Ventricular Drain Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Acute External Ventricular Drain Market: Pipeline Analysis

Chapter 4. U.S. Acute External Ventricular Drain Market: Application Estimates & Trend Analysis

• 4.1. Application Segment Dashboard
• 4.2. U.S. Acute External Ventricular Drain Market: Application Movement Analysis
• 4.3. U.S. Acute External Ventricular Drain Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. Traumatic Brain Injury
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
• 4.5. Subarachnoid Hemorrhage
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Intracerebral Hemorrhage
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Non-Traumatic Hydrocephalus Conditions
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Acute External Ventricular Drain Market: Patient Type Estimates & Trend Analysis

• 5.1. Patient Type Segment Dashboard
• 5.2. U.S. Acute External Ventricular Drain Market: Patient Type Movement Analysis
• 5.3. U.S. Acute External Ventricular Drain Market Size & Trend Analysis, by Patient Type, 2018 to 2030 (USD Million)
• 5.4. Pediatric
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Adult
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Medtronic
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Integra LifeSciences Corporation
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Anuncia Medical, Inc.
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Natus
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Fuji Systems
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. B Braun/Aesculap
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Boston Scientific
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Abbott
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives